The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) Lead Academic Site is to create a supportive environment that will foster 1) scientific leadership and mentorship, 2) development of cooperative group clinical trials, 3) substantial accrual to clinical trials across the entire NCTN and 4) exceptional conduct of clinical trials. Investigators at WU/SCC are committed to work to enhance the research goals of the NCTN Program and to enroll patients to NCTN trials across the Network. WU/SCC investigators have a long history of enthusiastic participation in the cooperative groups including ACOSOG, ACRIN, CALGB, GOG, and RTOG and will continue to play key roles in the newly merged groups including the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 U10 Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Bryan F. Meyers, MD, MPH (Professor, Thoracic Oncology), Jeff M. Michalski, MD, MBA (Professor, Radiation Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology) and Barry A. Siegel, MD (Professor, Radiology). All members of the senior leadership team have extensive clinical trial experience, including many years of cooperative group involvement, and are committed to providing guidance for an institution-wide cooperative group NCTN UI0. WU/SCC is consistently among the top accruing institutions in each of the cooperative groups with outstanding accrual across many disease sites. Between January 2007 and June 2012, WU/SCC accrued 1633 patients to cooperative group therapeutic trials, an average of 297 patients per year for the last 5.5 years (171 ACOSOG, 1024 CALGB/Alliance, 156 GOG, and 282 RTOG). During this same interval, 727 patients had biospecimens collected and 101 patients were accrued to advanced imaging studies through ACRIN. WU/SCC investigators are highly motivated to contribute to the scientific mission of the NCTN, particularly in the areas of breast cancer, gynecological oncology, thoracic oncology, Gl oncology, GU oncology, leukemia, and lymphoma. Strong translational science in breast cancer, lung cancer, and AML at WU/SCC, along with large institutional biorepositories, will provide many opportunities for unique contributions to correlative studies associated with cooperative group therapeutic trials. This institution-wide UIO will facilitate enhanced communication and collaboration among disease site and modality specialists and improve our potential for contributions to the NCTN operation.
SCC is the only NCI-designated Comprehensive Cancer Center in Missouri or Southern Illinois and it is the leading oncology treatment facility within th St. Louis metropolitan area. Participation in the NCTN allows WU/SCC physicians to offer a broad range of clinical trials to patients with all types and stages of cancer and also provides an opportunity for investigators to confirm preliminary institutional findings regarding new cancer treatments, diagnostic tools, and prognostic markers in large numbers of patients.
|Desseroit, Marie-Charlotte; Tixier, Florent; Weber, Wolfgang A et al. (2017) Reliability of PET/CT Shape and Heterogeneity Features in Functional and Morphologic Components of Non-Small Cell Lung Cancer Tumors: A Repeatability Analysis in a Prospective Multicenter Cohort. J Nucl Med 58:406-411|
|Walker, Christopher J; O'Hern, Matthew J; Serna, Vanida A et al. (2017) Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. Oncotarget 8:68758-68768|
|Gerber, David E; Urbanic, James J; Langer, Corey et al. (2017) Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). Clin Lung Cancer 18:333-339|
|Uy, Geoffrey L; Katz, Matthew H G; Boughey, Judy C (2017) Junior investigators: Get engaged in the Alliance for Clinical Trials in Oncology. Bull Am Coll Surg 102:62-3|
|Baggstrom, Maria Q; Socinski, Mark A; Wang, Xiaofei F et al. (2017) Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). J Thorac Oncol 12:843-849|
|Oliver, Kate E; Brady, William E; Birrer, Michael et al. (2017) An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol 147:243-249|
|Scheuermann, Joshua S; Reddin, Janet S; Opanowski, Adam et al. (2017) Qualification of National Cancer Institute-Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials. J Nucl Med 58:1065-1071|
|Thaker, Premal H; Brady, William E; Lankes, Heather A et al. (2017) A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal Gynecol Oncol 147:283-290|
|McCourt, Carolyn K; Deng, Wei; Dizon, Don S et al. (2017) A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 144:101-106|
|Li, Jing; Xing, Xiaoyun; Li, Daofeng et al. (2017) Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. Neoplasia 19:100-111|
Showing the most recent 10 out of 98 publications